Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Topoisomerase II Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
DNA topoisomerases are a group of enzymes that control DNA topology. DNA topoisomerase II has the ability to untangle double strands of DNA, due to which they are involved in many crucial nuclear processes such as transcription, replication or recombination. Topoisomerase II inhibitors bind to the N-terminal ATPase subunit of topoisomerase II, preventing the release of the separated DNA strands from the topoisomerase II dimer. Topoisomerase II inhibitors are indicated for infections of upper respiratory tract, urinary tract, and prostate, also for neoplastic conditions like leukaemia, lymphoma, breast cancer, neuroblastomas, carcinoma, sarcoma and others. Teva Pharmaceutical, CSPC Pharma, Orient Europharma, GSK, BMS, Kyowa Kirin International, and Daiichi Sankyo Company are some of the major players in the topoisomerase II inhibitors market.
Key Market Developments:
Approved Drug Molecules and Brand Names for Topoisomerase II Inhibitors:
Drugs under the Pipeline for Topoisomerase II Inhibitors:
Clinical Activity and Developments of Topoisomerase II Inhibitors:
Currently, there are more than 50 drug products in the topoisomerase II inhibitors, including 18 approved drug products and the rest of them are in the clinical development phases.
Molecule Name |
Number of Studies |
Myocet (Non-Pegylated Liposomal Doxorubicin) |
85 |
Vyxeos (Cytarabine/Daunorubicin liposomal formulation) |
76 |
Duoenda (Mitoxantrone liposomal) |
51 |
Duomeisu (Pegylated Liposomal Doxorubicin) |
26 |
Aldoxorubicin (INNO-206) |
25 |
Calsed (Amrubicin) |
22 |
Gepotidacin (GSK2140944) |
22 |
Pixuvri (Pixantrone) |
20 |
Tirazone (Tirapazamine) |
20 |
Qinprezo (vosaroxin) |
17 |
ThermoDox (Lyso-Thermosensitive Liposomal Doxorubicin) |
16 |
Veyonda (Idronoxil) |
10 |
Valrubicin |
9 |
Berubicin (RTA 744) |
8 |
Quinamed (Amonafide) |
6 |
Zoptrex (Zoptarelin Doxorubicin) |
5 |
Doxorubicin (SGN-15) |
5 |
Ofloxacin oral |
5 |
Zabolante (Zabofloxacin) |
3 |
anti-HER2 antibody conjugated with Pegylated Liposomal Doxorubicin (MM-302) |
3 |
Camsirubicin (MNPR-201) |
3 |
Sabarubicin (MEN10755) |
3 |
Avarofloxacin (JNJ-Q2) |
2 |
Glutathione PEGylated Liposomal Doxorubicin (2X-111) |
2 |
Milatuzumab-Doxorubicin antibody-drug conjugate (hLL1-DOX) |
2 |
F14512 |
1 |
HF158K1 |
1 |
IT-141 |
1 |
SQ3370 |
1 |
T-1201 |
1 |
THE001 |
1 |
Talidox (Doxorubicin liposomal) |
1 |
Camptothecin/Podophyllotoxin (NEV-801) |
1 |
Etoposide Toniribate (CAP7.1) |
1 |
Pro-Doxorubicin (AVA6000) |
1 |
Topoisomerase II inhibitors such as Doxorubicin, Donorubicin, Epirubicin, Idarubicin, and others are indicated in the treatment of neoplastic conditions such as acute lymphoblastic leukaemia, acute myeloblastic leukaemia, hodgkin and non-hodgkin lymphoma, metastatic breast cancer, metastatic Wilms tumor, metastatic neuroblastoma, metastaic soft tissue and bone sarcomas, metastatic ovarian carcinoma, thyroid cancer, gastric cancer, bladder carcinoma. Drugs such as ofloxacin, levofloxacin, gatifloxacin, ciprofloxacin, and others are used for the treatment of various infections caused by susceptible bacteria, including infections of the upper respiratory tract, skin, urinary tract, eye, and prostate.
Download Free Sample Report
Doxorubicin hydrochloride, Etoposide IV, Epirubicin, Levofloxacin, Daunorubicin, Mitoxantrone, Idarubicin hydrochloride, Ciprofloxacin oral, Dactinomycin are some of the approved topoisomerase II inhibitors.
Teva Pharmaceutical, CSPC Pharma, Orient Europharma, GSK, BMS, Kyowa Kirin International, and Daiichi Sankyo Company are some of the major players in the topoisomerase II inhibitors market.
Major indications for topoisomerase II inhibitors are acute lymphoblastic leukaemia, acute myeloblastic leukaemia, hodgkin and non-hodgkin lymphoma, metastatic breast cancer, metastatic Wilms tumor, metastatic neuroblastoma, various infections caused by susceptible bacteria, including infections of the upper respiratory tract, skin, urinary tract, eye, and prostate.
There are more than 30 molecules in the clinical development phases for topoisomerase II inhibitors.
Key Market Players